EGR2

Overview

EGR2 (Early Growth Response 2) is a zinc-finger transcription factor that plays a role in B cell development and induces apoptosis. It has been identified as a novel driver candidate in chronic lymphocytic leukemia (CLL), where loss-of-function mutations may impair apoptotic signaling and contribute to tumor survival.

Alterations observed in the corpus

  • Identified as a novel CLL driver candidate in a WES study of 160 CLL tumors (Broad cohort); EGR2 mutations are predicted to impair apoptosis induction; validation in independent cohorts noted as needed PMID:23415222
  • Previously reported as a candidate CLL driver but not confirmed as a PFS hit in the CLL8 chemoimmunotherapy trial cohort (n=538 patients) PMID:26466571

Cancer types (linked)

  • CLL: Novel driver candidate identified by exome sequencing of 160 tumors; mutations implicate disrupted apoptotic signaling PMID:23415222

Co-occurrence and mutual exclusivity

Therapeutic relevance

  • No targeted therapies currently linked to EGR2 in this corpus. Functional role in apoptosis suggests potential relevance to BH3-mimetic strategies.

Open questions

  • Validation of EGR2 as a bona fide CLL driver in independent cohorts is explicitly noted as outstanding PMID:23415222

Sources

This page was processed by entity-page-writer on 2026-05-06. - PMID:26466571

This page was processed by wiki-cli on 2026-05-14.